Global Gastrointestinal Partnering 2014-2019: Deal trends, players and financials - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 8, 2019--The “Global Gastrointestinal Partnering 2014-2019: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
Global Gastrointestinal Partnering 2014 to 2019 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
- Trends in Gastrointestinal partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Gastrointestinal partnering agreement structure
- Gastrointestinal partnering contract documents
- Top Gastrointestinal deals by value
- Most active Gastrointestinal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.
The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Global Gastrointestinal Partnering 2014 to 2019 includes:
- Trends in Gastrointestinal dealmaking in the biopharma industry since 2014
- Analysis of Gastrointestinal deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Gastrointestinal deal contract documents
- Comprehensive access to over 3500 Gastrointestinal deal records
- The leading Gastrointestinal deals by value since 2014
- Most active Gastrointestinal dealmakers since 2014
The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulcer, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.
In Global Gastrointestinal Partnering 2014 to 2019, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
For more information about this report visit https://www.researchandmarkets.com/r/dmrphv
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005358/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Gastrointestinal Drugs
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/08/2019 05:49 AM/DISC: 05/08/2019 05:50 AM